Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
53 studies found for:    "Temporal arteritis"
Show Display Options
Rank Status Study
21 Completed Impact of Vasculitis on Employment and Income
Conditions: Vasculitis;   Systemic Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis;   Temporal Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa (PAN);   Takayasu's Arteritis;   Urticarial Vasculitis
Intervention: Other: online questionnaire
22 Completed MRI Superficial Temporal Artery
Condition: Temporal Arteritis
Intervention: Device: MRI
23 Recruiting Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Condition: Giant Cell Arteritis
Intervention: Other: color Doppler ultrasound and TAB in case of CDU negative
24 Recruiting Improving the Diagnosis and Prognostication of GCA Through the Novel Use of PET Scan and Immune Biomarkers
Condition: Giant Cell Arteritis
25 Unknown  Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Conditions: Purpura, Schoenlein-Henoch;   Graft Versus Host Disease;   Anemia, Hemolytic, Autoimmune;   Rheumatoid Arthritis;   Churg-Strauss Syndrome;   Hypersensitivity Vasculitis;   Wegener's Granulomatosis;   Systemic Lupus Erythematosus;   Giant Cell Arteritis;   Pure Red Cell Aplasia;   Juvenile Rheumatoid Arthritis;   Polyarteritis Nodosa;   Autoimmune Thrombocytopenic Purpura;   Takayasu Arteritis
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: filgrastim;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Autologous Peripheral Blood Stem Cell Transplantation
26 Enrolling by invitation VCRC Patient Contact Registry Patient-Reported Data Validation Study
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Giant Cell Arteritis;   Wegener Granulomatosis;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
27 Completed Educational Needs of Patients With Systemic Vasculitis
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Vasculitis, Central Nervous System;   Giant Cell Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
28 Completed Vasculitis Illness Perception (VIP) Study
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu's Arteritis;   Henoch-Schoenlein Purpura;   Behcet's Disease;   CNS Vasculitis
29 Completed Reproductive Health in Men and Women With Vasculitis
Conditions: Giant Cell Arteritis;   Takayasu's Arteritis;   Polyarteritis Nodosa;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Behcet's Disease;   Kawasaki Disease;   Henoch-schoenlein Purpura;   Vasculitis, Central Nervous System;   Drug-induced Necrotizing Vasculitis
30 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
31 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
32 Completed Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
Conditions: Rheumatoid Arthritis;   Polymyalgia Rheumatica;   Giant Cell Arteritis;   Polymyositis;   Wegener’s Granulomatosis
Intervention: Drug: Alendronate versus alfacalcidol (1-alpha OH vitamin D)
33 Recruiting Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease
Condition: Horton's Disease
Intervention: Biological: Blood samples
34 Not yet recruiting Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Condition: Polymyalgia Rheumatica
Interventions: Drug: Tocilizumab;   Drug: Placebo
35 Not yet recruiting Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
Condition: Polymyalgia Rheumatica
Interventions: Drug: Sirukumab;   Drug: Placebo to match sirukumab;   Drug: Prednisone /Prednisone placebo
36 Completed Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica
Condition: Polymyalgia Rheumatica
Intervention: Drug: tocilizumab
37 Recruiting Delayed Release Prednisone in PMR
Condition: Polymyalgia Rheumatica
Interventions: Drug: Delayed-Release (DR) Prednisone;   Drug: Immediate Release (IR) Prednisone
38 Recruiting Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease
Condition: Horton Disease
Interventions: Radiation: Vascular tomodensitometry;   Other: Magnetic resonance angiography;   Other: Vascular ultrasonography;   Other: Retinal angiography;   Other: Retinal optical coherence tomography
39 Unknown  Study of the T CD8 Immune Response in Horton's Disease
Condition: Horton's Disease
Interventions: Other: Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment;   Other: 16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment;   Other: Blood sample drawn into a 5 mL dry tube;   Other: 16 blood samples drawn into 6 mL heparinized tubes
40 Unknown  Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Conditions: Horton's Disease;   Infectious Disease;   Neoplasia;   Solid Tumor;   Hemopathy
Interventions: Other: 1 blood sample;   Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-53) Show next page of results    Last Page
Indicates status has not been verified in more than two years